Accelerated absorption of regular insulin administered via a vascularizing permeable microchamber implanted subcutaneously in diabetic *Rattus*

norvegicus

- 1 Short title: Rapid insulin absorption via a subcutaneously implanted microchamber in *R. norvegicus*
- 2 **Leah V. Steyn¹ , Delaney Drew¹ , Demetri Vlachos¹ , Barry Huey¹ , Katie Cocchi¹ , Nicholas D.**
- 3 **Price¹ , Robert Johnson² , Charles W. Putnam¹ , and Klearchos K. Papas1,2***
- 4 1 Institute for Cellular Transplantation, Department of Surgery, University of Arizona College of
- 5 Medicine-Tucson, University of Arizona, Tucson, AZ, USA
- 6 ²Procyon Technologies, LLC., Medical Research Building (Room 121), University of Arizona,
- 7 Tucson, AZ, USA
- 8 *****Corresponding author
- 9 Email: kkpapas@surgery.arizona.edu (KPP)
- 10 **Keywords: insulin, diabetes, microchamber, subcutaneous, rat, absorption, vascularizing,**
- 11 **pharmacokinetics**

It is made available under a CC-BY 4.0 International license.

¹² **Abstract**

It is made available under a CC-BY 4.0 International license.

³³ **Introduction**

It is made available under a CC-BY 4.0 International license.

76 discussed in detail; they include, among many others: variations in the depth of needle penetration,

77 including inadvertent intramuscular injection; dislodged catheters or mechanical issues associated

78 with insulin pump infusion sets [39]; and seepage of drug from the injection site. It stands to reason 79 that intra-patient variability compounds inter-patient dosage algorithms; predictions and comparisons 80 are therefore fraught, requiring complex modeling [40, 41].

81 To address the challenges posed by lagging absorption of even ultra-fast insulins and the 82 inconsistency of intrasubject dosing, we evaluated in a diabetic *R. norvegicus* model, subcutaneously 83 implantable vascularizing microchambers, IVMs (Fig 1A). These microchambers – of various 84 footprints and capacities – are engineered of polytetrafluoroethylene membranes (PTFE) and have a 85 surface configuration which promotes angiogenic ingrowth; an inner membrane simultaneously 86 blocks host cells from entering and occupying the microchamber [42]. We report here that the IVM, 87 implanted in the SC space, accelerates the absorption of inexpensive regular human insulin, 88 achieving pharmacokinetic profiles potentially superior to ultra-rapid acting insulins. Importantly, 89 our data also suggest that the IVM improves consistency of insulin delivery, thereby potentially 90 avoiding hazardous deviations in blood glucose concentration. 91 92 **Fig 1. The Procyon implantable vascularizing microchamber (IVM) and an illustrative clinical** 93 **application.** 94 (A) The vascularizing, microchamber (depicted before implantation), fabricated of PTFE, has a

95 surface area per side of 1.5 cm² and a nominal volume of $22.5\mu L$. (B) One potential clinical

96 application of the IVM is to couple it with an insulin pump. The *infusion set* connects the *insulin*

- 97 *pump* to the SC implanted *microchamber*; the IVM's *connection tubing* is fitted with a *heal in place*
- 98 *cuff* fabricated from material that promotes vascularization. (C) A schematic of the vascularized
- 99 microchamber, depicting the ingrowth of blood vessels to its surface and the flow of insulin from

It is made available under a CC-BY 4.0 International license.

100 within the microchamber, through the permeable membranes, and into the richly vascularized SC

101 space surrounding the IVM.

102

¹⁰³ **Materials and methods**

104 **Experimental animals**

109 Animal Care and Use Committee (IACUC) at The University of Arizona.

110 **Induction of diabetes**

111 To avoid endogenous insulin in subject rats from cross-reacting in the human insulin assays, 112 animals were rendered diabetic by a single intraperitoneal injection, 60 mg/kg, of streptozotocin 113 (Sigma-Aldrich, St. Louis, MO, USA). Blood glucose concentrations were monitored daily using a 114 Freestyle Lite Glucose Monitoring System (Abbott Diabetes Care Inc., Alameda, CA, USA). Rats 115 were considered diabetic when blood glucose concentrations greater than 200 mg/dL were recorded 116 on three consecutive days. Rats verified as diabetic were maintained with exogenous long-acting 117 insulin (Lantus, Sanofi-Aventis, Bridgewater, NJ, USA) throughout the study; maintenance insulin 118 treatment also serves to forestall insulin resistance [43]. Maintenance insulin therapy was suspended 119 for 24 hours prior to each insulin kinetics study.

It is made available under a CC-BY 4.0 International license.

120 **Implantation of vascularizing microchambers (IVMs)**

125 **Insulin kinetics assays**

126 **Subcutaneous injection of human insulin**

127 The initial insulin kinetics assays were performed 7 days after STZ induction of diabetes. 128 Nonfasted rats received a single subcutaneous injection of insulin human, 1.5 U/kg (Humulin R; 129 Lilly, Indianapolis, IN, USA). Each dose of insulin was diluted in 0.5 mL of sterile saline (0.9%) 130 solution, then injected subcutaneously using a glass Hamilton syringe fitted with a 20-gauge sharp 131 needle.

132 **Blood sample collection**

133 Blood samples (150 μ L) were collected from the tail vein before injection (time = 0), and at 5-,

134 15-, 30-, 60-, 90-, and 120-minutes following injection. Blood samples for insulin assays were stored

- 135 on ice in 1.5 mL centrifuge tubes with EDTA until separation of plasma by centrifugation at 13,300 x
- 136 g for 15 minutes at 4°C. Plasma samples were stored at -20°C.

137 **Administration of human insulin via subcutaneously implanted IVMs**

It is made available under a CC-BY 4.0 International license.

138 On day 28 post-implantation, each rat received a single dose of insulin human, Humulin R, 1.5 139 U/kg (Lilly, Indianapolis, IN, USA), diluted as described above. The insulin was then instilled into 140 one of the two IVMs via its port. Blood samples for plasma insulin were collected and processed as 141 described above.

142 **Analysis of rat plasma samples for human insulin concentration**

143 Plasma samples collected from each insulin kinetics assay were analyzed for human insulin

144 concentration using a commercial human insulin ELISA kit (Alpco, Salem, NH, USA). Samples

145 were run in duplicate. The ELISA kit has a detection range of 3.0-200 µIU/mL and a sensitivity of

146 0.399 uIU/mL. The measured insulin concentrations were converted from IU/mL to ug/mL

147 according to the manufacturer's recommended conversion ratios of 1 IU of human insulin = 6nmol = 148 34.8 µg of insulin.

149 **IVM retrieval and histopathology**

150 At the conclusion of the study (day 40), rats were euthanized, and the IVMs were retrieved for 151 histology. Additional specimens were obtained 7 and 21 days after implantation from rats in a cohort 152 not included in the insulin analyses reported herein. After removal, each IVM including its adherent 153 tissue was placed in 10% neutral buffered formalin for fixation, then processed for paraffin 154 embedding. Paraffin blocks were sectioned and 5µM slices were collected throughout the 155 microchamber. Sections were stained with hematoxylin and eosin and imaged with a Keyence BZ-156 X710 microscope (Keyence Co, Osaka, Japan).

157 **Statistical analysis**

It is made available under a CC-BY 4.0 International license.

158 **Insulin kinetic curves**

165 **Peak insulin times and concentrations**

166 The mean peak times (T_{max}) and concentrations of the insulin kinetic assays were obtained as 167 follows: for each subject the greatest plasma insulin concentration was identified, and both the time 168 point (*e.g.*, 10 min) and the insulin concentration at that time point were tabulated. The mean and SD 169 for each category were then calculated. The two assays, subcutaneous injection at day -2, and IVM 170 administration on day 28, were compared by the unpaired, two-tailed, t-test. The full kinetic curves 171 were compared with the nonparametric Friedman's test [44]. Statistical tests were conducted with 172 GraphPad Prism version 9.4.1 for Windows (GraphPad Software, San Diego, California USA, 173 www.graphpad.com).

¹⁷⁴ **Results**

175 **Insulin-kinetics study after subcutaneous (SC) injection in diabetic rats**

176 Five days after successful induction of STZ diabetes, rats were injected subcutaneously with 177 diluted human insulin (Humulin R), followed by blood sampling for plasma insulin concentration 178 over a two-hour period. Consonant with the extensive literature documenting inter-subject variability

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

190

191 **Fig 2. Plasma insulin kinetics after either SC or IVM injection of regular insulin.**

192 Plasma concentrations of human insulin were collected over 120 minutes following either 193 subcutaneous injection (A,C) or instillation into subcutaneous IVMs 28 days after implantation (B,D) 194 of regular insulin human (Humulin R) in identical doses. Shown in A and B are the data for the 195 individual subjects in each group of rats; in C and D are the insulin kinetic curves generated by 196 plotting means and standard deviations (SD). N=11 rats in the SC injection group (one rat was 197 excluded from the analysis because of incomplete plasma insulin concentration data); N=12 rats in 198 the IVM group.

200 **Table 1**. **Mean peak times and concentrations of plasma insulin after subcutaneous or IVM**

201 **injection in diabetic rats of insulin human (1.5 U/kg body weight).**

202 Given are means, standard deviations (SD), and 95% Confidence Intervals (CI). Although the peak 203 concentrations are not significantly different (NS), the interval to peak concentration (**T***max*) was 204 significantly shorter (** p=0.0020, by the unpaired, two-tailed t test) when insulin was delivered via 205 microchamber.

206

207 **Insulin kinetics after administration via a subcutaneous microchamber**

208 The implantable vascularizing microchamber (IVM) by Procyon (Fig 1A) is designed to 209 provide a means for rapid, consistent absorption of insulin without repeated needle (or pen or pump 210 cannula) injections; it measures 1.5 cm² in surface area per side. Its surface is engineered to promote 211 rapid vascularization. Published reports suggested that to be effectively vascularized, subcutaneously 212 implanted devices typically require three to four weeks in mice [45, 46], two to four weeks in rats 213 [47], and two months or less in primates [48]. We therefore conducted the insulin kinetics assays at 214 28 days after implantation, anticipating mature vascularization by that time. Diluted insulin human

It is made available under a CC-BY 4.0 International license.

215 was instilled into the IVM at the same dose by body weight as in the SC injection control studies, 216 described above.

226 **Evidence of vascularization revealed by histopathology of retrieved**

227 **IVMs**

228 The peak insulin data presented in the preceding section strongly support the notion that 229 vascularization of the SC tissues surrounding and invading the vascularizing membranes of the 230 microchambers had matured by 28 days and had thereby facilitated the very rapid uptake of insulin. 231 If so, histologic evidence of blood vessels immediately adjacent to the microchambers is likewise 232 expected in the same time frame.

233 To examine this supposition, IVMs implanted subcutaneously in rats for 7, 21 and 40 days 234 were retrieved and examined histologically. Although the 1.5 cm²microchambers were identical to 235 the ones used for insulin kinetics studies, they had not been injected with insulin to avoid

It is made available under a CC-BY 4.0 International license.

²⁵⁴ **Discussion**

255 Here we report that a small (1.5 cm² surface area per side), specially engineered PTFE, 256 vascularizing microchamber (Fig 1) implanted subcutaneously facilitates more rapid uptake of

It is made available under a CC-BY 4.0 International license.

257 insulin than conventional SC injection. The IVM recruits the growth of blood vessels which establish 258 a surrounding vasculature, which fully matures by about one month (Fig 3). Regular insulin human 259 (Humulin R), when instilled into the IVM 28 days after implantation, achieves peak plasma 260 concentrations significantly faster than an identical dose delivered by conventional SC injection, 7.50 261 versus 22.7 min (Fig 2, Table 1). Additionally, inter-subject variability was reduced (Fig 2A,B). We 262 therefore conclude that the subcutaneously implanted microchambers are functionally mature within 263 weeks, not months.

264 The subcutaneous space is favored for insulin injection for patient convenience: it is a large 265 space readily accessible for injection and easily examined for problems at the sites of skin 266 penetration. Physiologically, however, it is less than ideal; its vascularity is both sparse and 267 heterogenous. Moreover, repeated injections may generate inflammation and consequent fibrosis, 268 rendering the microenvironment even less conducive to absorption of injected insulin. Finally, 269 utilizing the SC space for insulin delivery currently requires repeated injections, by needle, pen or 270 pump, their frequency depending upon the chosen insulin formulation(s) and the means of injection.

271 The primary clinical scenario for which we envisage the IVM achieving clinical utility for 272 T1DM patients (Fig 1) is a conceptual extension of the experiments described in this report – namely, 273 implantation in diabetic patients to facilitate the very rapid uptake of regular insulin. One might argue 274 that accelerating absorption via an IVM is an unnecessary redundancy now that ultra-rapid acting 275 insulins are available. However, the very rapid peak plasma insulin concentrations achieved with 276 regular insulin via IVM more closely mimic the normal human pancreas and are likely superior to 277 even ultra-rapid acting insulins injected SC [16, 49, 50]. The insulin kinetic curves (Fig 2 B, D) are 278 compatible with an "inject-eat continuum" strategy: this would, first, synchronize the insulin peak 279 with the prandial requirement; and second, avoid the pitfalls of inopportune delays of a meal by

It is made available under a CC-BY 4.0 International license.

280 simply postponing the injection. As shown in Fig 1, an insulin pump is easily connected to an IVM, 281 ensuring rapid uptake of the pumped insulin; this would allow greater precision in dosing and rapid 282 uptake of prandial boluses. Other challenging clinical scenarios would likewise benefit from rapid 283 uptake of insulin and therefore better glucose control. One example is insulin therapy of diabetics 284 during pregnancy, where precise glucose homeostasis is vital to the well-being, both immediate and 285 long-term, of mother and fetus [51].

286 Another argument sometimes made is that rapid uptake of insulin confers more risk than 287 benefit, for example, by triggering hypoglycemic episodes. However, the clinical safety and efficacy, 288 especially in post-prandial control, of ultra-rapid acting insulins is now supported by many studies 289 [15, 16, 52, 53]. The factitious "too rapid" assertion also deflects the many advances in continuous 290 glucose monitoring (CGM) devices, insulin dosage-predicting algorithms, precision-dosing insulin 291 pumps, open and closed loop systems, and the "artificial pancreas" (AP) [6]. To this point, a recent, 292 comprehensive review of multiple input AP systems [54], identified two persistent challenges: lag 293 times in acquiring blood glucose concentration data, and delays in absorption of insulin from SC 294 depots. Our study is relevant to the latter concern, which echoes an earlier sentiment: for APs (and 295 similar approaches) to achieve their full potential, the "applied insulin should induce ideally an 296 instantaneous effect" [4]. The IVM potentially offers a clinical means of further closing the gap 297 between insulin dose and blood glucose response.

²⁹⁸ **Conclusion**

299 Regular insulin human instilled into SC implantable vascularizing microchambers (IVMs) 300 implanted 28 days previously in diabetic rats attains mean peak plasma insulin concentrations in 7.5 301 (SD 4.50) min, versus 22.7 (SD 14.2) min following conventional SC injection. Inter-subject

It is made available under a CC-BY 4.0 International license.

302 variability was likewise reduced. Histologically, mature vascularization was evident at 21 and 40

303 days after implantation, indicating that neovascularization surrounding the IVMs contributed to the

304 rapidity of insulin uptake. We suggest that the implantable vascularizing microchambers reported

305 herein have clinical potential for the painless, repetitive, reproduceable delivery of regular insulin

306 with an absorption rate potentially exceeding that of ultra-rapid acting insulins.

³⁰⁷ **Acknowledgements**

308 The authors wish to acknowledge Chan A. Ion and Jennifer Kitzmann-Miner for their assistance in

309 preparing graphic work.

³¹⁰ **References**

311 1. Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, Cobelli C, et al.

312 Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes.

313 2012;61(9):2269-79. Epub 20120611. doi: 10.2337/db11-1462. PubMed PMID: 22688333; PubMed

314 Central PMCID: PMCPMC3425431.

315 2. Linsley PS, Greenbaum CJ, Nepom GT. Uncovering Pathways to Personalized Therapies in 316 Type 1 Diabetes. Diabetes. 2021;70(4):831-41. doi: 10.2337/db20-1185. PubMed PMID: 33741606; 317 PubMed Central PMCID: PMCPMC7980192.

318 3. Kramer CK, Retnakaran R, Zinman B. Insulin and insulin analogs as antidiabetic therapy: A 319 perspective from clinical trials. Cell Metab. 2021;33(4):740-7. doi: 10.1016/j.cmet.2021.03.014. 320 PubMed PMID: 33826916.

321 4. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci 322 Technol. 2012;6(4):728-42. Epub 20120701. doi: 10.1177/193229681200600402. PubMed PMID: 323 22920797; PubMed Central PMCID: PMCPMC3440142.

324 5. Luijf YM, van Bon AC, Hoekstra JB, Devries JH. Premeal injection of rapid-acting insulin 325 reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care. 2010;33(10):2152-5. 326 Epub 20100806. doi: 10.2337/dc10-0692. PubMed PMID: 20693354; PubMed Central PMCID: 327 PMCPMC2945151.

328 6. Domingo-Lopez DA, Lattanzi G, L HJS, Wallace EJ, Wylie R, O'Sullivan J, et al. Medical 329 devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus. Adv 330 Drug Deliv Rev. 2022;185:114280. Epub 20220408. doi: 10.1016/j.addr.2022.114280. PubMed 331 PMID: 35405298.

It is made available under a CC-BY 4.0 International license.

332 7. Becker RH, Frick AD, Burger F, Scholtz H, Potgieter JH. A comparison of the steady-state 333 pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine,

- 334 and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin
- 335 Endocrinol Diabetes. 2005;113(5):292-7. doi: 10.1055/s-2005-865637. PubMed PMID: 15926116.
- 336 8. Bode BW. Comparison of pharmacokinetic properties, physicochemical stability, and pump 337 compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine. Endocr Pract. 338 2011;17(2):271-80. doi: 10.4158/ep10260.Ra. PubMed PMID: 21134878.
- 339 9. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, et al. Monomeric insulins 340 obtained by protein engineering and their medical implications. Nature. 1988;333(6174):679-82. doi: 341 10.1038/333679a0. PubMed PMID: 3287182.
- 342 10. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al. Insulin aspart (B28 343 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared 344 with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501-6. doi: 345 10.2337/diacare.22.9.1501. PubMed PMID: 10480516.
- 346 11. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical 347 science. Diabetes Obes Metab. 2009;11(1):5-19. doi: 10.1111/j.1463-1326.2008.01015.x. PubMed 348 PMID: 19120431.
- 349 12. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of 350 diabetes: insulin analogs. Endocr Rev. 2001;22(5):706-17. doi: 10.1210/edrv.22.5.0442. PubMed 351 PMID: 11588149.
- 352 13. Kildegaard J, Buckley ST, Nielsen RH, Povlsen GK, Seested T, Ribel U, et al. Elucidating the 353 Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide. Pharm Res. 354 2019;36(3):49. Epub 20190211. doi: 10.1007/s11095-019-2578-7. PubMed PMID: 30746556; 355 PubMed Central PMCID: PMCPMC6373292.
- 356 14. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and 357 clinical implications. Diabetes Care. 1990;13(9):923-54. doi: 10.2337/diacare.13.9.923. PubMed 358 PMID: 2226110.
- 359 15. Wong EY, Kroon L. Ultra-Rapid-Acting Insulins: How Fast Is Really Needed? Clin Diabetes. 360 2021;39(4):415-23. doi: 10.2337/cd20-0119. PubMed PMID: 34866783; PubMed Central PMCID: 361 PMCPMC8603316.
- 362 16. Heise T, Piras de Oliveira C, Juneja R, Ribeiro A, Chigutsa F, Blevins T. What is the value of 363 faster acting prandial insulin? Focus on ultra rapid lispro. Diabetes Obes Metab. 2022. Epub 364 20220519. doi: 10.1111/dom.14773. PubMed PMID: 35593434.
- 365 17. Narayan RJ. Transdermal delivery of insulin via microneedles. J Biomed Nanotechnol. 366 2014;10(9):2244-60. doi: 10.1166/jbn.2014.1976. PubMed PMID: 25992456.
- 367 18. Malone JI, Lowitt S, Grove NP, Shah SC. Comparison of insulin levels after injection by jet 368 stream and disposable insulin syringe. Diabetes Care. 1986;9(6):637-40. doi:
- 369 10.2337/diacare.9.6.637. PubMed PMID: 3542456.
- 370 19. Pehling GB, Gerich JE. Comparison of plasma insulin profiles after subcutaneous
- 371 administration of insulin by jet spray and conventional needle injection in patients with insulin-
- 372 dependent diabetes mellitus. Mayo Clin Proc. 1984;59(11):751-4. doi: 10.1016/s0025-
- 373 6196(12)65585-2. PubMed PMID: 6387316.

It is made available under a CC-BY 4.0 International license.

374 20. Dirnena-Fusini I, Åm MK, Fougner AL, Carlsen SM, Christiansen SC. Physiological effects 375 of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A 376 systematic review and meta-analysis. PLoS One. 2021;16(4):e0249611. Epub 20210413. doi: 377 10.1371/journal.pone.0249611. PubMed PMID: 33848314; PubMed Central PMCID: 378 PMCPMC8043377. 379 21. van Dijk PR, Logtenberg SJ, Gans RO, Bilo HJ, Kleefstra N. Intraperitoneal insulin infusion: 380 treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia. Clin 381 Endocrinol (Oxf). 2014;81(4):488-97. Epub 20140728. doi: 10.1111/cen.12546. PubMed PMID: 382 25041605. 383 22. Al-Tabakha MM. Future prospect of insulin inhalation for diabetic patients: The case of 384 Afrezza versus Exubera. J Control Release. 2015;215:25-38. Epub 20150726. doi: 385 10.1016/j.jconrel.2015.07.025. PubMed PMID: 26222134. 386 23. Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an 387 ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012;6(4):773-9. Epub 20120701. doi: 388 10.1177/193229681200600406. PubMed PMID: 22920801; PubMed Central PMCID: 389 PMCPMC3440146. 390 24. Bally L, Thabit H, Hovorka R. Finding the right route for insulin delivery - an overview of 391 implantable pump therapy. Expert Opin Drug Deliv. 2017;14(9):1103-11. Epub 20161207. doi: 392 10.1080/17425247.2017.1267138. PubMed PMID: 27911116; PubMed Central PMCID: 393 PMCPMC5581917. 394 25. Spaan N, Teplova A, Stam G, Spaan J, Lucas C. Systematic review: continuous 395 intraperitoneal insulin infusion with implantable insulin pumps for diabetes mellitus. Acta Diabetol. 396 2014;51(3):339-51. Epub 20140305. doi: 10.1007/s00592-014-0557-3. PubMed PMID: 24595518. 397 26. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 398 2002;4(5):673-82. doi: 10.1089/152091502320798312. PubMed PMID: 12450450. 399 27. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject 400 variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 401 diabetes. Diabetes. 2004;53(6):1614-20. doi: 10.2337/diabetes.53.6.1614. PubMed PMID: 15161770. 402 28. Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in 403 intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-404 administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther. 405 2011;13(10):1039-45. Epub 20110629. doi: 10.1089/dia.2011.0115. PubMed PMID: 21714645. 406 29. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 407 2003;26(6):1902-12. doi: 10.2337/diacare.26.6.1902. PubMed PMID: 12766131. 408 30. Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size 409 of the problem. Diabetes Metab Res Rev. 2004;20 Suppl 2:S32-42. doi: 10.1002/dmrr.514. PubMed 410 PMID: 15551297. 411 31. Han D, Rahimi E, Aramideh S, Ardekani AM. Transport and Lymphatic Uptake of 412 Biotherapeutics Through Subcutaneous Injection. J Pharm Sci. 2022;111(3):752-68. Epub 20211006. 413 doi: 10.1016/j.xphs.2021.09.045. PubMed PMID: 34624293.

414 32. Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients.

415 Influence of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull. 416 1991;38(4):337-46. PubMed PMID: 1914533.

417 33. Hildebrandt P. Skinfold thickness, local subcutaneous blood flow and insulin absorption in 418 diabetic patients. Acta Physiol Scand Suppl. 1991;603:41-5. PubMed PMID: 1789128.

419 34. Hildebrandt PR, Vaag AA. Local skin-fold thickness as a clinical predictor of depot size 420 during basal rate infusion of insulin. Diabetes Care. 1993;16(1):1-3. doi: 10.2337/diacare.16.1.1.

421 PubMed PMID: 8422761.

422 35. Gradel AKJ, Porsgaard T, Brockhoff PB, Seested T, Lykkesfeldt J, Refsgaard HHF. Delayed 423 insulin absorption correlates with alterations in subcutaneous depot kinetics in rats with diet-induced 424 obesity. Obes Sci Pract. 2019;5(3):281-8. Epub 20190318. doi: 10.1002/osp4.326. PubMed PMID: 425 31275602; PubMed Central PMCID: PMCPMC6587326.

426 36. Hajheydari Z, Kashi Z, Akha O, Akbarzadeh S. Frequency of lipodystrophy induced by 427 recombinant human insulin. Eur Rev Med Pharmacol Sci. 2011;15(10):1196-201. PubMed PMID: 428 22165682.

429 37. Radermecker RP, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of 430 continuous insulin infusion and new insulin analogs. Am J Clin Dermatol. 2007;8(1):21-8. doi: 431 10.2165/00128071-200708010-00003. PubMed PMID: 17298103.

432 38. Gradel AKJ, Porsgaard T, Lykkesfeldt J, Seested T, Gram-Nielsen S, Kristensen NR, et al. 433 Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability. J 434 Diabetes Res. 2018;2018:1205121. Epub 20180704. doi: 10.1155/2018/1205121. PubMed PMID: 435 30116732; PubMed Central PMCID: PMCPMC6079517.

436 39. Kanapka LG, Lum JW, Beck RW. Insulin Pump Infusion Set Failures Associated with 437 Prolonged Hyperglycemia: Frequency and Relationship to Age and Type of Infusion Set During 438 22,741 Infusion Set Wears. Diabetes Technol Ther. 2022;24(6):396-402. Epub 20220223. doi: 439 10.1089/dia.2021.0548. PubMed PMID: 35104166.

440 40. García-Jaramillo M, Calm R, Bondia J, Vehí J. Prediction of postprandial blood glucose 441 under uncertainty and intra-patient variability in type 1 diabetes: a comparative study of three interval 442 models. Comput Methods Programs Biomed. 2012;108(1):224-33. Epub 20120605. doi: 443 10.1016/j.cmpb.2012.04.003. PubMed PMID: 22677264.

444 41. Zheng H, Nathan DM, Schoenfeld DA. Using a multi-level B-spline model to analyze and 445 compare patient glucose profiles based on continuous monitoring data. Diabetes Technol Ther. 446 2011;13(6):675-82. Epub 20110413. doi: 10.1089/dia.2010.0199. PubMed PMID: 21488799; 447 PubMed Central PMCID: PMCPMC3101946.

448 42. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC. 449 Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed 450 Mater Res. 1995;29(12):1517-24. doi: 10.1002/jbm.820291208. PubMed PMID: 8600142.

451 43. Nordquist L, Sjöquist M. Improvement of insulin response in the streptozotocin model of

452 insulin-dependent diabetes mellitus. Insulin response with and without a long-acting insulin

453 treatment. Animal. 2009;3(5):685-9. doi: 10.1017/s175173110800387x. PubMed PMID: 22444446.

It is made available under a CC-BY 4.0 International license.

454 44. Friedman M. The Use of Ranks to Avoid the Assumption of Normality Implicit in the 455 Analysis of Variance. Journal of the American Statistical Association. 1937;32(200):675-701. doi: 456 10.1080/01621459.1937.10503522. 457 45. Hussey AJ, Winardi M, Han XL, Thomas GP, Penington AJ, Morrison WA, et al. Seeding of 458 pancreatic islets into prevascularized tissue engineering chambers. Tissue Eng Part A. 459 2009;15(12):3823-33. doi: 10.1089/ten.TEA.2008.0682. PubMed PMID: 19558221. 460 46. Pepper AR, Pawlick R, Gala-Lopez B, MacGillivary A, Mazzuca DM, White DJ, et al. 461 Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a 462 Subcutaneous Cell Pouch Device. Transplantation. 2015;99(11):2294-300. doi: 463 10.1097/tp.0000000000000864. PubMed PMID: 26308506; PubMed Central PMCID: 464 PMCPMC4623852. 465 47. Rafael E, Wernerson A, Arner P, Tibell A. In vivo studies on insulin permeability of an 466 immunoisolation device intended for islet transplantation using the microdialysis technique. Eur Surg 467 Res. 1999;31(3):249-58. doi: 10.1159/000008700. PubMed PMID: 10352353. 468 48. Sasikala M, Rao GV, Vijayalakshmi V, Pradeep R, Pothani S, Kumar PP, et al. Long-term 469 functions of encapsulated islets grafted in nonhuman primates without immunosuppression. 470 Transplantation. 2013;96(7):624-32. doi: 10.1097/TP.0b013e31829e26cf. PubMed PMID: 23883970. 471 49. Bolli GB, Porcellati F, Lucidi P, Fanelli CG, Owens DR. One-hundred year evolution of 472 prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs. Metabolism. 473 2022;126:154935. Epub 20211108. doi: 10.1016/j.metabol.2021.154935. PubMed PMID: 34762931. 474 50. Owens DR, Bolli GB. The continuing quest for better subcutaneously administered prandial 475 insulins: a review of recent developments and potential clinical implications. Diabetes Obes Metab. 476 2020;22(5):743-54. Epub 20200203. doi: 10.1111/dom.13963. PubMed PMID: 31930670; PubMed 477 Central PMCID: PMCPMC7187182. 478 51. Amigó J, Corcoy R. Type 1 diabetes and pregnancy: An update on glucose monitoring and 479 insulin treatment. Endocrinol Diabetes Nutr (Engl Ed). 2022. Epub 20220701. doi: 480 10.1016/j.endien.2022.06.008. PubMed PMID: 35787359. 481 52. Avgerinos I, Papanastasiou G, Karagiannis T, Michailidis T, Liakos A, Mainou M, et al. 482 Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. Diabetes 483 Obes Metab. 2021;23(10):2395-401. Epub 20210622. doi: 10.1111/dom.14461. PubMed PMID: 484 34105242. 485 53. De Block CEM, Van Cauwenberghe J, Bochanen N, Dirinck E. Rapid-acting insulin 486 analogues: Theory and best clinical practice in type 1 and type 2 diabetes. Diabetes Obes Metab. 487 2022. Epub 20220411. doi: 10.1111/dom.14713. PubMed PMID: 35403348. 488 54. Hettiarachchi C, Daskalaki E, Desborough J, Nolan CJ, O'Neal D, Suominen H. Integrating 489 Multiple Inputs Into an Artificial Pancreas System: Narrative Literature Review. JMIR Diabetes. 490 2022;7(1):e28861. Epub 20220224. doi: 10.2196/28861. PubMed PMID: 35200143; PubMed Central 491 PMCID: PMCPMC8914747.

Figure 1

Figure 2

Figure 3